You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on ALK biomarkers.
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.
A big bump in service revenues made up for a decline in product revenues. The company also trimmed its operating expenses and narrowed its net loss.
The assay can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori.
Using mass spec and small hairpin RNA, they built a map of ALK signaling and identified proteins that could sensitize tumor cells to inhibitor treatment.
Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.
Repeat molecular analysis of a patient's cancer helped clinicians guide targeted therapies as drug resistance emerged and ebbed.
Genentech's Alecensa and AstraZeneca's Tegrisso are the latest precision lung cancer drugs, and Xalkori might soon be an option for a new molecular subpopulation.
The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations.
In developing the recommendations, the expert panel attempted to keep up with the fast-moving advances in oncology.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.